Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer

Loma Al-Mansouri, Howard Gurney

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Prostate cancer is the most common malignancy in male patients. The second-generation taxanes, cabazitaxel, is a therapeutic option with an overall survival advantage for patients with metastatic castration-resistant prostate cancer. This review explores specific aspects of cabazitaxel including the duration of treatment, the efficacy of lower dose and effect on the incidence of adverse effects, and optimal sequencing of cabazitaxel. A systematic search of data baselines “PubMed, Ovid Medline, Scopus, and Embase” was carried out using the keywords “cabazitaxel” and “metastatic prostate cancer.” The search was limited to clinical studies performed after October 2010 addressing duration of treatment, the efficacy of lower dose, adverse effects, the sequence of cabazitaxel in relation to other lines of therapy and use in chemotherapy naïve patients. The current evidence supports the utility and safety of cabazitaxel as either a second- or third-line agent after docetaxel, or as an alternative to docetaxel in the chemotherapy-naive setting. Extended duration of cabazitaxel beyond 10 cycles is feasible and does not appear to lead to cumulative toxicity. In conclusion, cabazitaxel can improve survival in castrate-resistant prostate cancer with an acceptable risk of toxicity. Studies confirmed the efficacy of reduced dose and utility in patients without prior chemotherapy.

LanguageEnglish
Number of pages8
JournalAsia-Pacific Journal of Clinical Oncology
DOIs
Publication statusE-pub ahead of print - 16 Jul 2019

Fingerprint

Castration
Prostatic Neoplasms
docetaxel
Drug Therapy
Taxoids
Survival
cabazitaxel
PubMed
Safety
Incidence
Therapeutics

Keywords

  • cabazitaxel
  • chemotherapy naïve
  • duration of treatment
  • metastatic castration-resistant prostate cancer
  • number of cycles
  • reduced dose
  • sequence of therapy

Cite this

@article{e669f427681949319a7ac2d14e4a7e79,
title = "Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer",
abstract = "Prostate cancer is the most common malignancy in male patients. The second-generation taxanes, cabazitaxel, is a therapeutic option with an overall survival advantage for patients with metastatic castration-resistant prostate cancer. This review explores specific aspects of cabazitaxel including the duration of treatment, the efficacy of lower dose and effect on the incidence of adverse effects, and optimal sequencing of cabazitaxel. A systematic search of data baselines “PubMed, Ovid Medline, Scopus, and Embase” was carried out using the keywords “cabazitaxel” and “metastatic prostate cancer.” The search was limited to clinical studies performed after October 2010 addressing duration of treatment, the efficacy of lower dose, adverse effects, the sequence of cabazitaxel in relation to other lines of therapy and use in chemotherapy na{\"i}ve patients. The current evidence supports the utility and safety of cabazitaxel as either a second- or third-line agent after docetaxel, or as an alternative to docetaxel in the chemotherapy-naive setting. Extended duration of cabazitaxel beyond 10 cycles is feasible and does not appear to lead to cumulative toxicity. In conclusion, cabazitaxel can improve survival in castrate-resistant prostate cancer with an acceptable risk of toxicity. Studies confirmed the efficacy of reduced dose and utility in patients without prior chemotherapy.",
keywords = "cabazitaxel, chemotherapy na{\"i}ve, duration of treatment, metastatic castration-resistant prostate cancer, number of cycles, reduced dose, sequence of therapy",
author = "Loma Al-Mansouri and Howard Gurney",
year = "2019",
month = "7",
day = "16",
doi = "10.1111/ajco.13193",
language = "English",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell, Wiley",

}

Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer. / Al-Mansouri, Loma; Gurney, Howard.

In: Asia-Pacific Journal of Clinical Oncology, 16.07.2019.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer

AU - Al-Mansouri, Loma

AU - Gurney, Howard

PY - 2019/7/16

Y1 - 2019/7/16

N2 - Prostate cancer is the most common malignancy in male patients. The second-generation taxanes, cabazitaxel, is a therapeutic option with an overall survival advantage for patients with metastatic castration-resistant prostate cancer. This review explores specific aspects of cabazitaxel including the duration of treatment, the efficacy of lower dose and effect on the incidence of adverse effects, and optimal sequencing of cabazitaxel. A systematic search of data baselines “PubMed, Ovid Medline, Scopus, and Embase” was carried out using the keywords “cabazitaxel” and “metastatic prostate cancer.” The search was limited to clinical studies performed after October 2010 addressing duration of treatment, the efficacy of lower dose, adverse effects, the sequence of cabazitaxel in relation to other lines of therapy and use in chemotherapy naïve patients. The current evidence supports the utility and safety of cabazitaxel as either a second- or third-line agent after docetaxel, or as an alternative to docetaxel in the chemotherapy-naive setting. Extended duration of cabazitaxel beyond 10 cycles is feasible and does not appear to lead to cumulative toxicity. In conclusion, cabazitaxel can improve survival in castrate-resistant prostate cancer with an acceptable risk of toxicity. Studies confirmed the efficacy of reduced dose and utility in patients without prior chemotherapy.

AB - Prostate cancer is the most common malignancy in male patients. The second-generation taxanes, cabazitaxel, is a therapeutic option with an overall survival advantage for patients with metastatic castration-resistant prostate cancer. This review explores specific aspects of cabazitaxel including the duration of treatment, the efficacy of lower dose and effect on the incidence of adverse effects, and optimal sequencing of cabazitaxel. A systematic search of data baselines “PubMed, Ovid Medline, Scopus, and Embase” was carried out using the keywords “cabazitaxel” and “metastatic prostate cancer.” The search was limited to clinical studies performed after October 2010 addressing duration of treatment, the efficacy of lower dose, adverse effects, the sequence of cabazitaxel in relation to other lines of therapy and use in chemotherapy naïve patients. The current evidence supports the utility and safety of cabazitaxel as either a second- or third-line agent after docetaxel, or as an alternative to docetaxel in the chemotherapy-naive setting. Extended duration of cabazitaxel beyond 10 cycles is feasible and does not appear to lead to cumulative toxicity. In conclusion, cabazitaxel can improve survival in castrate-resistant prostate cancer with an acceptable risk of toxicity. Studies confirmed the efficacy of reduced dose and utility in patients without prior chemotherapy.

KW - cabazitaxel

KW - chemotherapy naïve

KW - duration of treatment

KW - metastatic castration-resistant prostate cancer

KW - number of cycles

KW - reduced dose

KW - sequence of therapy

UR - http://www.scopus.com/inward/record.url?scp=85069657012&partnerID=8YFLogxK

U2 - 10.1111/ajco.13193

DO - 10.1111/ajco.13193

M3 - Review article

JO - Asia-Pacific Journal of Clinical Oncology

T2 - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

ER -